http://www.recercat.cat:80/handle/2072/179328 Tue, 21 May 2013 08:29:05 GMT 2013-05-21T08:29:05Z http://www.recercat.cat:80/bitstream/id/44950/ http://www.recercat.cat:80/handle/2072/179328 http://www.recercat.cat:80/handle/2072/203118 Clinical pharmacokinetics of mycophenolic acid and its metabolites in solid organ transplant recipient Colom Codina, Helena; Lloberas Blanch, Núria; Caldés, Ana; Andreu, Franc; Torras Ambròs, Joan; Oppenheimer Salinas, Federico; Sanchez-Plumed, Jaime; Gentil, Miguel A.; Kuypers, Dirk R.; Brunet i Serra, Mercè; Ekberg, Henrik; Grinyo Boira, Josep M. Mycophenolate mofetil (MMF), an ester prodrug of the immunosuppressant mycophenolic acid (MPA), is widely used for maintenance immunosuppressive therapy and prevention of renal allograft rejection in renal transplant recipients.MPA inhibits inosine monophosphate dehydrogenase (IMPDH), an enzyme involved in the “de novo” synthesis of purine nucleotides, thus suppressing both T-cell and B-cell proliferation. MPA shows a complex pharmacokinetics with considerable interand intra- patient by between- and within patient variabilities associated to MPA exposure. Several factors may contribute to it. The pharmacokinetic modeling according to the population pharmacokinetic approach with the non-linear mixed effects models has shown to be a powerful tool to describe the relationships between MMF doses and the MPA exposures and also to identify potential predictive patients’ demographic and clinical characteristics for dose tailoring during the post-transplant immunosuppresive treatment.; Podeu consultar el llibre complet a: http://hdl.handle.net/2445/32393 http://www.recercat.cat:80/handle/2072/203118 http://www.recercat.cat:80/handle/2072/203079 Recent advances in pharmaceutical sciences II Muñoz-Torrero López-Ibarra, Diego (ed.); Haro Bautista, Diego (ed.); Vallès Xirau, Joan, 1959- http://www.recercat.cat:80/handle/2072/203079 http://www.recercat.cat:80/handle/2072/203078 Recent advances in pharmaceutical sciences Muñoz-Torrero López-Ibarra, Diego (ed.) http://www.recercat.cat:80/handle/2072/203078 http://www.recercat.cat:80/handle/2072/179530 Technological, biopharmaceutical and pharmacokinetic advances: new formulations of application on the skin and oral mucosa Calpena Campmany, Ana Cristina; Clares, Beatriz; Fernández, Francisco Currently a growing interest to improve the pharmacological therapy exists, not only by the production and the appearance of new drugs, but guaranteeing that the uses of those which already exist, become more effective. In fact, the conventional pharmaceutical formulations of different drugs present a few secondary effects due to oral administration. In order to avoid these undesired side effects, the purpose of current therapeutic is the development and research of formulations as an alternative to others routes of administration. Therefore, in spite of the undoubtedly complete parenteral absorption, the transdermal and transbuccal routes appear to be a rather attractive alternative to provide an efficient absorption. In this chapter a new technological, biopharmaceutical and pharmacokinetic approach of strategies for application on skin and buccal mucosa are reported. In the future new transdermal drug delivery systems will emerge to be more effective, equipped with an improved aesthetic appearance, better adherence and greater diffusion. But to reach these aims, it is necessary previous knowledge of histology and physiology of skin, and factors involved in the penetration of drugs through it.; Podeu consultar el llibre complet a: http://hdl.handle.net/2445/32392 http://www.recercat.cat:80/handle/2072/179530 http://www.recercat.cat:80/handle/2072/179529 Resveratrol: A polyphenol with multiple effects Planas i Rosselló, Joana M.; Colom Codina, Helena; Juan i Olivé, M. Emília trans-Resveratrol (trans-3,5,4'-trihydroxystilbene) is a natural polyphenol that occurs in grapes, berries, peanuts, and several traditional medicines. A number of studies have demonstrated that this polyphenol holds promise against numerous age-associated diseases including cancer, diabetes, Alzheimer, cardiovascular and pulmonary diseases. In view of these studies, resveratrol's prospects for use in the clinics are rapidly accelerating. This review summarizes our work on the mechanisms involved in the intestinal absorption and its population pharmacokinetics. Finally, various targets of resveratrol and its therapeutic potential are described.; Podeu consultar el llibre complet a: http://hdl.handle.net/2445/32392 http://www.recercat.cat:80/handle/2072/179529